Quick Answer
Tenaya Therapeutics, Inc. reported Operating Income Loss of -$93.33 million for the year ending 2025.
- Tenaya Therapeutics, Inc. showed an increase of +19.5% in Operating Income Loss from 2024 to 2025.
- This data is from Tenaya Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 11, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 6 years of available data (2020 to 2025), Tenaya Therapeutics, Inc.'s Operating Income Loss has declined by 139.9%.
- Historical annual values: Fiscal year 2025: -$93.33 million | Fiscal year 2024: -$115.95 million | Fiscal year 2023: -$131.19 million | Fiscal year 2022: -$125.62 million | Fiscal year 2021: -$72.81 million | Fiscal year 2020: -$38.91 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: